Olesja Popow

Olesja Popow

Auto-generated profile, based on publicly available information

Olesja Popow

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
PLPatrick Loi
Patrick Loi
ASAmy E. Schade
Amy E. Schade
CRCarrie L. Rodriguez
Carrie L. Rodriguez
AKAnjana Krishnan
Anjana Krishnan
Naiara PerurenaNaiara Perurena
Naiara Perurena
KCKaren Cichowski
Karen Cichowski
Current treatments for KRAS-mutant colorectal cancers are often limited by cellular plasticity and rewiring responses. Here we describe a promising therapeutic strategy that simultaneously targets epigenetic and oncogenic signals. Specifically, we show that inhibitors of histone methyltransferase, EZH2, synergize with various rat sarcoma virus (RAS) pathway inhibitors and promote dramatic tumor regression in vivo. Together these agents cooperatively suppress Wingless and Int-1 (WNT)-driven transcription and drive colorectal cancers into a more differentiated cell state by inducing the Groucho/transducin-like enhancer corepressor, TLE4, along with a network of WNT pathway inhibitors and intestinal differentiation proteins. However, these agents also induce the proapoptotic protein BCL2 modifying factor (BMF), which subsequently kills these more differentiated cells. Accordingly, cell death can be prevented by activating β-catenin, by blocking differentiation, or by ablating BMF expression. Collectively, these studies reveal a new therapeutic approach for treating KRAS-mutant colorectal cancers and illustrate a critical convergence of EZH2 and RAS on oncogenic WNT signals, intestinal differentiation, and apoptosis. Significance: Combined EZH2 and RAS pathway inhibitors kill KRAS-mutant colorectal cancer cells and promote durable tumor regression in vivo. These agents function by cooperatively suppressing the WNT pathway, driving differentiation, and epigenetically reprogramming cells to permit the induction of apoptotic signals, which then kill these more differentiated tumor cells.

23 February 2022 in Molecular Cell
Verified
Journal Article
Closed access
CJChristian William Johnson
Christian William Johnson
HSHyuk-Soo Seo
Hyuk-Soo Seo
ETElizabeth M. Terrell
Elizabeth M. Terrell
MYMoon-Hee Yang
Moon-Hee Yang
FKFenneke KleinJan
Fenneke KleinJan
KHKevin M. Haigis
Kevin M. Haigis

3 June 2019 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
OPOlesja Popow
Olesja Popow
Joao A PauloJoao A Paulo
Joao A Paulo
MTMichael H. Tatham
Michael H. Tatham
MVMelanie S. Volk
Melanie S. Volk
ARAlejandro Rojas-Fernandez
Alejandro Rojas-Fernandez
INInke Näthke
Inke Näthke
Adenomatous Polyposis Coli (APC) is the most frequently mutated gene in colorectal cancer. APC negatively regulates the Wnt signaling pathway by promoting the degradation of β-catenin, but the extent to which APC exerts Wnt/β-catenin–independent tumor-suppressive activity is unclear. To identify interaction partners and β-catenin–independent targets of endogenous, full-length APC, we applied label-free and multiplexed tandem mass tag-based mass spectrometry. Affinity enrichment-mass spectrometry identified more than 150 previously unidentified APC interaction partners. Moreover, our global proteomic analysis revealed that roughly half of the protein expression changes that occur in response to APC loss are independent of β-catenin. Combining these two analyses, we identified Misshapen-like kinase 1 (MINK1) as a putative substrate of an APC-containing destruction complex. We validated the interaction between endogenous MINK1 and APC and further confirmed the negative, and β-catenin–independent, regulation of MINK1 by APC. Increased Mink1/Msn levels were also observed in mouse intestinal tissue and Drosophila follicular cells expressing mutant Apc/APC when compared with wild-type tissue/cells. Collectively, our results highlight the extent and importance of Wnt-independent APC functions in epithelial biology and disease. Implications: The tumor-suppressive function of APC, the most frequently mutated gene in colorectal cancer, is mainly attributed to its role in β-catenin/Wnt signaling. Our study substantially expands the list of APC interaction partners and reveals that approximately half of the changes in the cellular proteome induced by loss of APC function are mediated by β-catenin–independent mechanisms.

13 January 2026 in Cancer Research
Verified
Journal Article
Open access
RBRachel Abigail Burge
Rachel Abigail Burge
OROzgun Le Roux
Ozgun Le Roux
OPOlesja Popow
Olesja Popow
VSVictoria K. Spadafora
Victoria K. Spadafora
CRChristabelle Rajesh
Christabelle Rajesh
GHGuy Aaron Hobbs
Guy Aaron Hobbs
Patients with pancreatic ductal adenocarcinoma (PDAC) harboring KRASG12R mutations have increased overall survival relative to patients with KRASG12D/V mutations. To investigate the mechanisms underlying this differential outcome, we developed a genetically engineered mouse model (GEMM) harboring KrasG12R and Trp53R172H mutations (KrasLSL-G12R/+;Trp53LSL-R172H/+;p48Cre-ERTM). Unlike KrasG12D models, KrasG12R GEMMs exhibited limited tumorigenesis, with only 10% developing pancreatic tumors after 1 year. Additionally, mice harboring whole-body expression of KrasG12R remained healthy for over 1 year, whereas KrasG12D mice developed rapid multifocal disease. Comparison of KRAS mutant-selective transcription and signaling in murine and human PDAC cell lines, GEMMs, and patient-derived xenograft (PDX) mouse models revealed that direct KRAS-mediated PI3K activation is necessary for robust tumor initiation in GEMMs. Unexpectedly, KRAS was not the primary driver of PI3K activity in human PDAC cell lines and PDX models, regardless of KRAS mutation. KRASG12R and KRASG12D activated a similar pancreas-specific transcriptional network, but KRASG12R promoted these pathways less robustly due to limited ERK/MAPK nuclear translocation. Finally, KRASG12R human pancreatic tumors had an altered tumor microenvironment (TME) with reduced collagen deposition and metastatic liver invasion. Together, this study demonstrated that KRASG12R is capable of driving tumorigenesis despite the reduced ERK/MAPK nuclear translocation and transcriptional output. Although human KRASG12D- and KRASG12R-mutant tumors display unexpected similarities in PI3K activity, the differential ERK/MAPK signaling activity and the extrinsic consequences on the TME provide support for using KRASG12R mutation status as a prognostic biomarker for therapeutic strategies. Significance: KRASG12R-mutant pancreatic cancer is characterized by lower ERK/MAPK nuclear translocation and transcriptional output than KRASG12D-mutant tumors, offering a potential window for patients with KRASG12R mutations to derive additional benefit from neoadjuvant therapy. See related commentary by Tiriac and Engle, p. 1817 See related article by Burge et al., p. 1854 See related article by Kamgar et al., p. 2042

25 July 2025 in bioRxiv
Verified
Preprint
Open access
OPOlesja Popow
Olesja Popow
QYQing Yu
Qing Yu
CYClarance Yapp
Clarance Yapp
SHShannon Hull
Shannon Hull
JPJoão A Paulo
João A Paulo
KHKevin M Haigis
Kevin M Haigis
SUMMARY: KRAS is among the most frequently mutated oncogenes in cancer. Yet, mutations in KRAS are common only in tumors originating from a subset of tissues. It is critical to understand the molecular mechanisms underlying this oncogene tissue specificity. Utilizing genetically engineered mouse models carrying a conditional oncogenic allele of Kras , we expressed activated K-Ras in adult tissues to investigate its specificity. We discovered that the ability of K-Ras G12D to influence the fitness of cells in a given tissue is not determined by its canonical signaling through MAPK. Instead, low baseline expression of c-Myc renders tissues non-permissive to oncogenic K-Ras, a context that can be reversed in the liver by ectopically expressing c-Myc. This functions independently of the proliferative index of the tissue or the induction of cell cycle arrest or apoptosis. Our findings reveal the importance of the basal state of the tissue-inherent signaling network for determining oncogene specificity.

17 June 2026
Verified
Other
Open access
PLPatrick Loi
Patrick Loi
ASAmy E. Schade
Amy E. Schade
CRCarrie L. Rodriguez
Carrie L. Rodriguez
AKAnjana Krishnan
Anjana Krishnan
Naiara PerurenaNaiara Perurena
Naiara Perurena
KCKaren Cichowski
Karen Cichowski
Extended data related to Figure 7.